US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Astellas Pharma, Inc.

12.88

+0.14001.10%

Volume:54.79K

Turnover:704.51K

Market Cap:23.06B

PE:173.23

High:12.90

Open:12.82

Low:12.82

Close:12.74

52wk High:13.07

52wk Low:8.37

Shares:1.79B

Float Shares:1.75B

Volume Ratio:0.57

T/O Rate:0.00%

Dividend:0.49

Dividend Rate:3.80%

EPS(TTM):0.0744

EPS(LYR):0.0628

ROE:7.95%

ROA:6.68%

PB:2.22

PE(LYR):204.96

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer

Astellas, Pfizer announces results from Phase 3 EV-303 trial for PADCEV

Yomiuri: Astellas Pharma Offers Leadership Training to Assist Patient Group Activities

Press Release: Astellas Announces Top Management Personnel Change

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALPMY"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALPMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","market":"US","secType":"STK","nameCN":"Astellas Pharma, Inc.","latestPrice":12.88,"timestamp":1764968400000,"preClose":12.74,"halted":0,"volume":54794,"delay":15,"floatShares":1745183156,"shares":1790310070,"eps":0.074352,"marketStatus":"Market Closed","change":0.14,"latestTime":"12-05 16:00:00 EST Delay","open":12.82,"high":12.9,"low":12.82,"amount":704511.4878000004,"amplitude":0.006279,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.074352,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":12.74,"volumeRatio":0.5703775099146448},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","floatShares":1745183156,"roa":"6.68%","roe":"7.95%","lyrEps":0.062841,"volumeRatio":0.5703775099146448,"shares":1790310070,"dividePrice":0.489212,"high":12.9,"amplitude":0.006279,"preClose":12.74,"low":12.82,"week52Low":8.37,"pbRate":"2.22","psRate":"1.79","week52High":13.07,"institutionHeld":0,"latestPrice":12.88,"eps":0.074352,"divideRate":0.037982,"volume":54794,"delay":15,"ttmEps":0.074352,"open":12.82,"prevYearClose":9.66,"prevWeekClose":12.55,"prevMonthClose":12.55,"prevQuarterClose":10.88,"fiveDayClose":12.55,"twentyDayClose":11.27,"sixtyDayClose":11.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALPMY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-04","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"","actualEps":null},{"date":"2024-08-01","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722499200000,"name":null,"time":"","dateTimestamp":1722484800000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-11-01","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1698811200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALPMY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALPMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1758171600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALPMY\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2585622140","title":"FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2585622140","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585622140?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:52","pubTimestamp":1763747520,"startTime":"0","endTime":"0","summary":"The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer .The FDA said Friday it has approved the drug combination as a treatment for before and after bladder-removal surgery in adult MIBC patients who are ineligible for cisplatin, a chemotherapy medication.A recent trial demonstrated statistically significant improvements in event-free survival and overall survival for patients with previously untreated MIBC who were treated with the drug combination before and after bladder-removal surgery and pelvic lymph node dissection, compared with surgery alone, the FDA said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU1035773651.USD","SG9999001440.SGD","IE000M9KFDE8.USD","LU0238689110.USD","SG9999015341.SGD","ALPMY","LU1066051811.HKD","LU2468319806.SGD","LU1571399168.USD","LU1941712264.USD","SG9999002224.SGD","LU1699723380.USD","MRK","LU1093756168.USD","LU1974910355.USD","LU0265550946.USD","IE00B4R5TH58.HKD","LU2023250504.SGD","SG9999015358.SGD","SG9999014567.USD","LU2461242641.AUD","BK4585","LU1116320901.HKD","SG9999001176.USD","LU1989772840.SGD","LU0861579265.USD","IE00BLSP4239.USD","BK4533","LU0208291251.USD","LU0234572021.USD","LU1023059063.AUD","IE00BBT3K403.USD","LU1037948897.HKD","LU1983299246.USD","LU2324357040.USD","LU1929549753.HKD","IE0002141913.USD","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","LU0320765489.SGD","LU0203345920.USD","BK4516","LU2089984988.USD","LU1989771016.USD","LU0965509283.SGD","LU2106854487.HKD","LU1291159041.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2576176006","title":"Astellas, Pfizer announces results from Phase 3 EV-303 trial for PADCEV","url":"https://stock-news.laohu8.com/highlight/detail?id=2576176006","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576176006?lang=en_us&edition=fundamental","pubTime":"2025-10-20 05:20","pubTimestamp":1760908807,"startTime":"0","endTime":"0","summary":"Astellas Pharma (ALPMY) and Pfizer (PFE) announced positive results from the Phase 3 EV-303 clinical trial for PADCEV, a Nectin-4 directed antibody...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astellas-pfizer-announces-results-from-phase-3-ev-303-trial-for-padcev-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astellas-pfizer-announces-results-from-phase-3-ev-303-trial-for-padcev-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","SG9999002224.SGD","LU0321505868.SGD","LU0225771236.USD","LU0234572021.USD","SG9999003800.SGD","IE0002270589.USD","LU0170899867.USD","BK4599","LU0122379950.USD","LU0289739699.SGD","LU0456855351.SGD","BK4550","LU1066053197.SGD","BK4585","SG9999011175.SGD","ALPMY","LU0321505439.SGD","BK4007","LU0306806265.USD","LU1057294990.SGD","SG9999001176.USD","LU0225284248.USD","SG9999002232.USD","BK4581","BK4588","LU1894683264.USD","IE000M9KFDE8.USD","PFE","SG9999001176.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","IE00BLSP4239.USD","BK4534","SG9999013999.USD","LU1883839398.USD","LU0985481810.HKD","LU0868494617.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1066051498.USD","BK4533","LU0306807586.USD","IE00BLSP4452.SGD","LU0058720904.USD","IE00B19Z3581.USD","BK4592"],"gpt_icon":0},{"id":"2575263346","title":"Yomiuri: Astellas Pharma Offers Leadership Training to Assist Patient Group Activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2575263346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575263346?lang=en_us&edition=fundamental","pubTime":"2025-10-14 14:19","pubTimestamp":1760422740,"startTime":"0","endTime":"0","summary":"Major Japanese pharmaceutical firm Astellas Pharma Inc. in Tokyo is offering unique training to support the development of personnel involved in patient group management to establish stable organizational foundations and sustain their activities.In fiscal 2021, it launched the leadership training program to equip participants with the knowledge and skills necessary for management. Participants can attend five free lectures per year, given by external instructors such as university faculty and human resource development consultants.The lectures cover topics like enhancing communication skills and approaches to organizational management. Over the past four events, a total of 72 participants from 51 groups have attended. This has led to tangible outcomes, such as participants presenting their activities at academic conferences gathering domestic specialist physicians and establishing connections with overseas patient groups.This article is from The Yomiuri Shimbun. Neither Dow Jones Newsw","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALPMY","BK4007"],"gpt_icon":0},{"id":"2571806997","title":"Press Release: Astellas Announces Top Management Personnel Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2571806997","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571806997?lang=en_us&edition=fundamental","pubTime":"2025-09-29 14:00","pubTimestamp":1759125600,"startTime":"0","endTime":"0","summary":"TOKYO, Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced the following changes to its Top Management structure, effective October 1, 2025.Nick Eshkenazi, current Chief Digital & Transformation Officer , will leave Astellas on September 30, 2025. Consequently, effective October 1, 2025, the position of CDTO will be removed from Top Management, with both Digital and Transformation functions being integrated into the Strategy function, led by Adam Pearson, the Chief Strategy Officer .In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from tho","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDO","CEO","BK4007","CFO","LU1861215975.USD","LU1861220033.SGD","BK4595","BK4585","BK4588","LU2290526834.HKD","BK4141","BK4596","BK4600","STRK","LU0053671581.USD","BK4023","ALPMY","BK4516","LU2360107168.USD"],"gpt_icon":1}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALPMY\",params:#limit:6,delay:false,,,undefined,":[]}}